Le Lézard
Classified in: Health
Subjects: POL, TRD, AVO

3 Reasons Innovation Depends On Strong IP Protections in the TPP



WASHINGTON, June 16, 2015 /PRNewswire-USNewswire/ -- As Congress continues to debate Trade Promotion Authority (TPA), it is important to keep in mind why the Trans-Pacific Partnership (TPP) ? the largest trade deal in history ? can and should help propel the United States (U.S.) into a new era of innovation and productivity in biopharmaceutical manufacturing.

3 Reasons Innovation Depends on Strong IP Protections in the TPP

Our industry's core mission is the discovery of new treatments and cures to help patients live longer, healthier lives. Below are three important facts to keep in mind about why upholding strong intellectual property (IP) protections as part of TPP are vital to the continued discovery and delivery of medicines for the world's patients:

#1. Creating life-saving medicines requires significant investment and resources. 
New medicines are the result of up to 15 years of complex research and development at an average cost of $2.6 billion. The U.S. and other nations must encourage and incentivize the innovation that has the potential to propel today's research into tomorrow's most cutting-edge treatments and cures.

#2. For medical innovation to continue, the TPP must uphold the strong IP protections that currently exist in the U.S. 
The important role of IP ? including a 12-year data protection period for biologics ? is not a new idea. In fact, it was codified in the Affordable Care Act, endorsed by a strong, bipartisan majority in Congress. 

#3. The evidence is overwhelming that the U.S. model works. 
Strong protection of IP is a catalyst for the creation of new medicines for the world's patients. In too many countries, patient access to medicines are stymied not by strong IP protections, but dynamics like poor infrastructure, lack of investment and high tariffs.  The robust IP protections afforded in the United States have helped foster a system whereby the U.S. dominates the pipeline of new drugs in development and, in turn, where generics comprise a healthy 85 percent-plus of the market.

As PhRMA CEO John Castellani notes this week in Morning Consult, we must continue to create an environment ripe for investment today to unlock the promising science of tomorrow. 

This post originally appeared here: http://catalyst.phrma.org/3-reasons-innovation-depends-on-strong-ip-protections-in-the-tpp.

Contact: Tina Stow; 202-835-3460; newsroom@phrma.org

Pharmaceutical Research and Manufacturers of America.

Photo - http://photos.prnewswire.com/prnh/20150616/223597

Logo - http://photos.prnewswire.com/prnh/20091027/PHRMALOGO

 

SOURCE Pharmaceutical Research and Manufacturers of America


These press releases may also interest you

23 oct 2017
DALLAS, Oct. 23, 2017 /PRNewswire/ -- HealthMine survey data underscores that the way members connect to health plans directly relates to how members prefer to receive help about their health.  Eighty-nine percent (89%) of those 64-years old and...

23 oct 2017
LAS VEGAS, Oct. 23, 2017 /PRNewswire-USNewswire/ -- The Economic Club of Las Vegas, a nationally renowned platform for economic discussion and debate, has announced it will host a panel of healthcare experts in Las Vegas on Thursday, October 26th,...

23 oct 2017
CARROLLTON, Texas, Oct. 23, 2017 /PRNewswire/ -- Hospice Source, LLC announced today that it has purchased certain assets of Specialized Medical Services and Premier Medical Corporation in the markets of East Tennessee, New Mexico, and Houston,...

23 oct 2017
GRAPEVINE, Texas, Oct. 23, 2017 /PRNewswire/ -- Support raised through Get in the Game, a luncheon aimed at increasing awareness of domestic violence resources available in North Texas, will assist The Gatehouse, a community supporting domestic...

23 oct 2017
NASHVILLE, Tenn., Oct. 23, 2017 /PRNewswire/ -- HealthCombix, a global decentralized healthcare development company, announced today Mr. Matthew Conboy has joined the company Advisory Board.   Mr. Conboy is a health care professional with a...

23 oct 2017
MILWAUKEE, Oct. 23, 2017 /PRNewswire-USNewswire/ -- Of the 981 physicians in the state of Wisconsin selected for the Best Doctors in America® 2017-2018 list, nearly two-thirds are Medical College of Wisconsin (MCW) faculty physicians and/or alumni....




News published on 16 june 2015 at 17:35 and distributed by: